H.C. Wainwright Reiterates a Buy Rating on Xoma Corp (XOMA)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Xoma Corp (XOMAResearch Report), with a price target of $30. The company’s shares opened today at $17.44.

Pantginis commented:

“We reiterate our Buy rating and $30 target. We highlight that we currently omit the 38 undisclosed partnered assets at the company, and look to provide potential contribution once identification and terms are delineated. Further, we do not include valuation contribution from projected cash flow from expected milestone payments from partners. Our clinical NPV model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -13.6% and a 27.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xoma Corp with a $27.50 average price target, which is a 57.7% upside from current levels. In a report issued on August 1, Wedbush also reiterated a Buy rating on the stock with a $25 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.66 and a one-year low of $11.02. Currently, Xoma Corp has an average volume of 84.06K.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of XOMA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.